Anticancer Drugs Cemiplimab-rwlc Medicine Oncology Pharmacology Physiotherapy

Cemiplimab-rwlc (Mechanism of Action)

In this article we will discuss Cemiplimab-rwlc (Mechanism of Action)

In this article, we will discuss Cemiplimab-rwlc (Mechanism of Action). So, let’s get started.

Mechanism of Action

Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.

Cemiplimab-rwlc is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.